Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab in Pediatric Aplastic Anemia
NCT06430788Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2024
- Primary completion
- May 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of emapalumab in aplastic anemia, sponsored by Memorial Sloan Kettering Cancer Center. Started May 2024; status: recruiting.
02
Drugs
emapalumab
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT06430788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06430788.